706 related articles for article (PubMed ID: 16469347)
1. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
2. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
4. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
5. Cloning, expression and purification of duck hepatitis B virus (DHBV) core protein and its use in the development of an indirect ELISA for serologic detection of DHBV infection.
Liu Q; Jia R; Wang M; Huang J; Zhu D; Chen S; Yin Z; Wang Y; Chen X; Cheng A
Arch Virol; 2014 May; 159(5):897-904. PubMed ID: 24158348
[TBL] [Abstract][Full Text] [Related]
6. Cellular immune response of ducks to duck hepatitis B virus infection.
Vickery K; Cossart Y; Dixon R
J Med Virol; 1999 May; 58(1):19-25. PubMed ID: 10223541
[TBL] [Abstract][Full Text] [Related]
7. The early host innate immune response to duck hepatitis B virus infection.
Tohidi-Esfahani R; Vickery K; Cossart Y
J Gen Virol; 2010 Feb; 91(Pt 2):509-20. PubMed ID: 19846670
[TBL] [Abstract][Full Text] [Related]
8. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
9. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.
Khawaja G; Buronfosse T; Jamard C; Abdul F; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans CF; Hartmann D; Cova L
Virology; 2012 Nov; 433(1):192-202. PubMed ID: 22921316
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of specific immune responses to duck hepatitis B virus in infected, immune, and uninfected ducks].
Tang N; Huang A; Guo S; Qi Z; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):166-8. PubMed ID: 11412394
[TBL] [Abstract][Full Text] [Related]
12. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
13. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
[TBL] [Abstract][Full Text] [Related]
14. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
15. Delipidation of a hepadnavirus: Viral inactivation and vaccine development.
Cham BE; Vickery K; Tohidi-Esfahani R; Cossart Y
J Virol Methods; 2006 Oct; 137(1):160-3. PubMed ID: 16808980
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the kinetics of the specific cellular immune response to duck hepatitis B virus in infected and immune ducks.
Vickery K; Cossart Y; Dixon R
Vet Microbiol; 1999 Aug; 68(1-2):157-69. PubMed ID: 10501173
[TBL] [Abstract][Full Text] [Related]
17. The effect of surgical immunomodulation on liver inflammation and clearance of DHBV infection.
Vickery K; Tohidi-Esfahani R; Pouliopoulos J; Welschinger R; Dixon R; Deva A; Cossart Y
J Med Virol; 2006 Dec; 78(12):1572-8. PubMed ID: 17063509
[TBL] [Abstract][Full Text] [Related]
18. Identification of T-cell epitopes associated with immunity within the surface protein of duck hepatitis B virus.
Welschinger R; Cossart Y; Pouliopoulos J; Dixon R; Vickery K
J Viral Hepat; 2006 Aug; 13(8):515-22. PubMed ID: 16901281
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of DNA vaccines against duck hepatitis B virus infection.
Triyatni M; Jilbert AR; Qiao M; Miller DS; Burrell CJ
J Virol; 1998 Jan; 72(1):84-94. PubMed ID: 9420203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
